Search | Clinical Trials Finder

Conditions: Acute Decompensated Heart Failure
Interventions: Experimental: Placebo, Experimental: Metolazone; Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Huntington Disease
Interventions: ACR16, Placebo; Drug · Other
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Birmingham, Alabama • San Diego, California • Littleton, Colorado + 18 more

Conditions: Adrenoleukodystrophy, Restless Legs Syndrome
Interventions: Pramipexole, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fibromyalgia, Persian Gulf Syndrome
Interventions: Low Dose Naltrexone, Placebo - sugar pill; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Depression, Major Depressive Disorder, Major Depression
Interventions: Arm 1, 2, 3 device interventions, Arm 2 Interventions, Arm 1, 2, 3 drug Interventions, Arm 1 and 2 Interventions; Device · Other · Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions: Micronized progesterone, Spironolactone, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prolonged Grief Disorder, Bereavement
Interventions: Syntocinon, Placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 55 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%; Drug
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 5
States / cities: Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more

Conditions: Malignant Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 5
States / cities: Springdale, Arkansas • San Francisco, California • Hackensack, New Jersey + 2 more

Conditions: Heart Failure
Interventions: Empagliflozin 10 mg, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Relapsed/Refractory Acute Myeloid Leukemia
Interventions: Nintedanib and AML induction; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 2
States / cities: New Haven, Connecticut • Nashville, Tennessee

Conditions: Hyperglycemia
Interventions: Metformin, Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC); Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy, Alzheimer Disease
Interventions: AL003, Saline Solution; Biological · Other
Lead sponsor: Alector Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 5
States / cities: Delray Beach, Florida • Lady Lake, Florida • Orlando, Florida + 2 more

Conditions: Healthy Volunteer, Atopic Dermatitis, Hidradenitis Suppurativa
Interventions: KT-474/Placebo, KT-474; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Sun City West, Arizona • Boynton Beach, Florida + 8 more

Conditions: Crohn's Disease
Interventions: MEDI2070, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 26
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 22 more

Conditions: Nicotine Dependence
Interventions: Intravenous Nicotine, Progesterone; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Anemia, Sickle Cell, Pain
Interventions: Fentanyl Citrate, Normal Saline; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Colorectal Neoplasms
Interventions: KD018, Irinotecan, Placebo; Drug
Lead sponsor: Edward Chu, MD; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: New Haven, Connecticut • Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions: E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.; Drug
Lead sponsor: Engeneic Pty Limited; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: El Segundo, California • Summit, New Jersey • New York, New York + 1 more

Conditions: Moderate to Severe Plaque-type Psoriasis
Interventions: secukinumab 150 mg, secukinumab 300 mg, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 18
States / cities: Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 15 more

Conditions: Methicillin-Resistant Staphylococcus Aureus
Interventions: Retapamulin, Placebo; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Irvine, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI, FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS, Placebo DISKUS, Placebo NDPI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Tucson, Arizona • Newport Beach, California • Riverside, California + 12 more

Conditions: Obstructive Sleep Apnea, Sleep
Interventions: Ketone-IQ, Placebo; Dietary Supplement
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Effects of Low Dose Naltrexone in Fibromyalgia

Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

Oxytocin and Approach-avoid in Grief

Safety and Efficacy of a Drug Delivery System in Glaucoma

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Effects of Acute and Chronic Empagliflozin Heart Failure

A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia

Metformin Use in Patients Undergoing Total Joint Replacement Surgery

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

First in Human Study for Safety and Tolerability of AL003.

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.

Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks

Retapamulin for Reducing MRSA Nasal Carriage

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Impact of Exogenous Ketones on Sleep Apnea